Literature DB >> 1349850

p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma.

A von Deimling1, R H Eibl, H Ohgaki, D N Louis, K von Ammon, I Petersen, P Kleihues, R Y Chung, O D Wiestler, B R Seizinger.   

Abstract

Loss of genetic material on the short arm of chromosome 17 is observed in approximately 40% of human astrocytomas (WHO grades II and III) and in approximately 30% of cases of glioblastoma multiforme (WHO grade IV). Previous studies of glioblastoma multiforme have shown that the p53 gene, located on the short arm of chromosome 17, is frequently mutated in these glioblastomas. To explore whether lower-grade astrocytomas are also associated with corresponding mutations of the p53 gene, we have investigated a series of 22 human astrocytomas of WHO grades II and III both for loss of heterozygosity on chromosome 17p and for p53 mutations. Mutations in the conserved regions of the p53 gene were identified by single strand conformation polymorphism analysis of exons 5, 6, 7, and 8 and were verified by direct DNA sequencing of the polymerase chain reaction products. p53 mutations were observed in 3 of 8 grade II astrocytomas and 4 of 14 grade II astrocytomas. In all 22 tumors, allelic loss of the short arm of chromosome 17 was investigated by restriction fragment length polymorphism analysis. One-half of the grade II astrocytomas (4 of 8) and grade III astrocytomas (7 of 14) exhibited allelic loss on chromosome 17p. Mutations in the p53 gene were exclusively observed in tumors with allelic loss on 17p. Our results show that p53 mutations are not restricted to glioblastoma multiforme and may be important in the tumorigenesis of lower-grade astrocytomas and that p53 mutations in lower-grade astrocytomas are associated with loss of chromosome 17p. These findings are consistent with a recessive mechanism of action of p53 in WHO grade II and III astrocytoma tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349850

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Molecular profile of oligodendrogliomas in young patients.

Authors:  Vaishali Suri; Prerana Jha; Shipra Agarwal; Pankaj Pathak; Mehar Chand Sharma; Vikas Sharma; Sudhanshu Shukla; Kumaravel Somasundaram; Ashok Kumar Mahapatra; Shashank Sharad Kale; Chitra Sarkar
Journal:  Neuro Oncol       Date:  2011-10       Impact factor: 12.300

3.  Defective p53 antiangiogenic signaling in glioblastoma.

Authors:  Benjamin Berger; David Capper; Dieter Lemke; Philipp-Niclas Pfenning; Michael Platten; Michael Weller; Andreas von Deimling; Wolfgang Wick; Markus Weiler
Journal:  Neuro Oncol       Date:  2010-05-26       Impact factor: 12.300

4.  Loss of heterozygosity for DNA polymorphisms mapping to chromosomes 10 and 17 and prognosis in patients with gliomas.

Authors:  C E Jones; M B Davis; J L Darling; J F Geddes; D G Thomas; A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

5.  Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.

Authors:  H Haapasalo; J Isola; P Sallinen; H Kalimo; H Helin; I Rantala
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

6.  Molecular genetic changes in a series of neuroepithelial tumors of childhood.

Authors:  Alessia Di Sapio; Isabella Morra; Luca Pradotto; Marilena Guido; Davide Schiffer; Alessandro Mauro
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

7.  Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds.

Authors:  Jessica J Hawes; John D Nerva; Karlyne M Reilly
Journal:  J Biomol Screen       Date:  2008-07-29

8.  Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway.

Authors:  R A Gjerset; H Fakhrai; D L Shawler; S Turla; O Dorigo; A Grover-Bardwick; D Mercola; S F Wen; H Collins; H Lin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-03       Impact factor: 2.416

9.  High frequency of temperature-sensitive mutants of p53 in glioblastoma.

Authors:  Jana Smardova; Kvetoslava Liskova; Barbora Ravcukova; Lenka Kubiczkova; Sabina Sevcikova; Jaroslav Michalek; Miluse Svitakova; Vaclav Vybihal; Leos Kren; Jan Smarda
Journal:  Pathol Oncol Res       Date:  2013-03-28       Impact factor: 3.201

10.  Alterations in tumour suppressor gene p53 in human gliomas from Indian patients.

Authors:  Poornima Phatak; S Kalai Selvi; T Divya; A S Hegde; Sridevi Hegde; Kumaravel Somasundaram
Journal:  J Biosci       Date:  2002-12       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.